NASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free FGEN Stock Alerts $1.14 +0.01 (+0.88%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.11▼$1.2250-Day Range$0.98▼$2.6452-Week Range$0.33▼$19.47Volume780,857 shsAverage Volume1.19 million shsMarket Capitalization$113.40 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get FibroGen alerts: Email Address FibroGen MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside1,391.2% Upside$17.00 Price TargetShort InterestBearish5.91% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.00Based on 4 Articles This WeekInsider TradingAcquiring Shares$95,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.09) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.53 out of 5 starsMedical Sector1603rd out of 5,424 stocksPharmaceutical Preparations Industry715th out of 2,550 stocks 2.9 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.91% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently increased by 4.62%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for FibroGen this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -77% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.39% of the stock of FibroGen is held by insiders.Percentage Held by Institutions72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($1.09) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings55x Gains Instead of 9x GainsWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. About FibroGen Stock (NASDAQ:FGEN)FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Read More FGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FGEN Stock News HeadlinesMay 4, 2024 | americanbankingnews.comFibroGen (FGEN) Scheduled to Post Quarterly Earnings on MondayMay 3, 2024 | msn.comFibroGen Q1 2024 Earnings PreviewMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 29, 2024 | globenewswire.comFibroGen to Report First Quarter 2024 Financial ResultsApril 24, 2024 | finance.yahoo.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 24, 2024 | globenewswire.comFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingApril 17, 2024 | msn.comFibroGen (FGEN) Price Target Increased by 40.00% to 1.79April 3, 2024 | markets.businessinsider.comFibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 3, 2024 | msn.comFibroGen falls after early-stage data for prostate cancer drugApril 3, 2024 | markets.businessinsider.comFibroGen (FGEN) Gets a Sell from Goldman SachsApril 2, 2024 | globenewswire.comFibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerMarch 26, 2024 | globenewswire.comFibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | investorplace.com3 Nightmare Nasdaq Stocks Not Worth Holding Another DayMarch 11, 2024 | finanznachrichten.deFibroGen, Inc.: FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerMarch 11, 2024 | markets.businessinsider.comFibroGen Appoints Deyaa Adib As CMOMarch 11, 2024 | globenewswire.comFibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerFebruary 29, 2024 | finance.yahoo.comUS$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest ResultsFebruary 29, 2024 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comFibroGen Full Year 2023 Earnings: Misses ExpectationsFebruary 27, 2024 | finanznachrichten.deFibroGen, Inc.: FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | finance.yahoo.comFibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023February 26, 2024 | reuters.comFibroGen regains rights to anemia drug from AstraZenecaFebruary 26, 2024 | globenewswire.comFibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comFibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaFebruary 25, 2024 | markets.businessinsider.comHere's what Wall Street expects from FibroGen's earnings reportFebruary 24, 2024 | finance.yahoo.comFGEN Jan 2026 1.000 callSee More Headlines Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today5/05/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees486Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$32.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,391.2%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-284,230,000.00 Net Margins-192.37% Pretax Margin-194.15% Return on EquityN/A Return on Assets-51.00% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.33 Sales & Book Value Annual Sales$147.75 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value($1.87) per share Price / Book-0.61Miscellaneous Outstanding Shares99,470,000Free Float97,097,000Market Cap$113.40 million OptionableOptionable Beta0.88 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Thane Wettig (Age 59)CEO & Director Comp: $941.79kMr. Juan Graham (Age 47)Senior VP & CFO Comp: $892.49kMs. Christine L. Chung (Age 56)Senior Vice President of China Operations Comp: $915.36kDr. Barry A. Berkowitz Ph.D.FounderDr. John J. Hunter Ph.D. (Age 61)Chief Scientific Officer David DeLuciaVice President of Corporate FP&A and Investor RelationsMr. Michael D. Lowenstein J.D.Ph.D., Chief Legal OfficerMs. Tricia StewartChief People OfficerMr. Kirk A. Christoffersen MBA (Age 55)Chief Business Officer Dr. Rahul Rajan Kaushik Ph.D.Senior Vice President of Pharmaceutical Development, Technical Operations & ManufacturingMore ExecutivesKey CompetitorsKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMSeres TherapeuticsNASDAQ:MCRBLianBioNASDAQ:LIANInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsSold 124,254 shares on 5/1/2024Ownership: 0.140%Mirae Asset Global Investments Co. Ltd.Bought 55,811 shares on 5/1/2024Ownership: 0.056%Simplex Trading LLCBought 37,900 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Sold 1,798,009 shares on 4/24/2024Ownership: 0.434%Accel Wealth ManagementBought 43,955 shares on 4/19/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions FGEN Stock Analysis - Frequently Asked Questions Should I buy or sell FibroGen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" FGEN shares. View FGEN analyst ratings or view top-rated stocks. What is FibroGen's stock price target for 2024? 4 brokerages have issued 12-month price targets for FibroGen's shares. Their FGEN share price targets range from $2.00 to $32.00. On average, they anticipate the company's share price to reach $17.00 in the next year. This suggests a possible upside of 1,391.2% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts. How have FGEN shares performed in 2024? FibroGen's stock was trading at $0.8863 at the start of the year. Since then, FGEN stock has increased by 28.6% and is now trading at $1.14. View the best growth stocks for 2024 here. Are investors shorting FibroGen? FibroGen saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 5,190,000 shares, a decline of 6.1% from the March 15th total of 5,530,000 shares. Based on an average daily volume of 2,740,000 shares, the short-interest ratio is presently 1.9 days. Currently, 5.7% of the company's stock are sold short. View FibroGen's Short Interest. When is FibroGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our FGEN earnings forecast. How can I listen to FibroGen's earnings call? FibroGen will be holding an earnings conference call on Monday, May 6th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) announced its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.15. The biopharmaceutical company earned $27.14 million during the quarter, compared to the consensus estimate of $40 million. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ). When did FibroGen IPO? FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. Who are FibroGen's major shareholders? FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.43%), BNP Paribas Financial Markets (0.14%), Mirae Asset Global Investments Co. Ltd. (0.06%), Accel Wealth Management (0.04%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr. View institutional ownership trends. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FGEN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
